A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-21

Study Completion Date

2019-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694

Healthy Volunteers Schizophrenia

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

NCT01879722

Schizophrenia

COMPLETED PHASE1

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

NCT02477020

Schizophrenia

COMPLETED PHASE2

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

NCT03382639

Schizophrenia

COMPLETED PHASE2

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

NCT03359785

Schizophrenia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called TAK-041. TAK-041 is being tested to treat people who have stable schizophrenia. This study will look whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved in people who take TAK-041 in addition to standard care.

The study will enroll approximately 32 patients. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment sequences -which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need) to receive either TAK-041 40 mg or Placebo first and then will be crossed over to receive the opposite Intervention.

All participants will be asked to take oral suspension on Day 1 of each Period. There will be a wash-out Period of 35 days between the dosing days in Period 1 and 2.

This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately 126 to 154 days. Participants will make multiple visits to the clinic plus a final visit 77 days after receiving their last dose of drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stable Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics

TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

Group Type EXPERIMENTAL

TAK-041

Intervention Type DRUG

TAK-041 suspension

Placebo

Intervention Type DRUG

TAK-041 placebo-matching suspension

Second Generation Antipsychotics (SGA)

Intervention Type DRUG

Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics

TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

Group Type EXPERIMENTAL

TAK-041

Intervention Type DRUG

TAK-041 suspension

Placebo

Intervention Type DRUG

TAK-041 placebo-matching suspension

Second Generation Antipsychotics (SGA)

Intervention Type DRUG

Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics

TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

Group Type EXPERIMENTAL

TAK-041

Intervention Type DRUG

TAK-041 suspension

Placebo

Intervention Type DRUG

TAK-041 placebo-matching suspension

Second Generation Antipsychotics (SGA)

Intervention Type DRUG

Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics

TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

Group Type EXPERIMENTAL

TAK-041

Intervention Type DRUG

TAK-041 suspension

Placebo

Intervention Type DRUG

TAK-041 placebo-matching suspension

Second Generation Antipsychotics (SGA)

Intervention Type DRUG

Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-041

TAK-041 suspension

Intervention Type DRUG

Placebo

TAK-041 placebo-matching suspension

Intervention Type DRUG

Second Generation Antipsychotics (SGA)

Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Is on a stable dose of antipsychotics for at least 2 months as documented by medical history and assessed by site staff (other than those on the excluded medication list).
2. Meets schizophrenia criteria as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by the Mini International Neuropsychiatric Interview (MINI).
3. Have Positive and Negative Syndrome Scale (PANSS) total score less than or equal to (\<=) 90 and PANSS Negative Symptom Factor Score (\[NSFS\]; Sum of PANSS N1, N2, N3, N4, N6, G7, and G16) greater than or equal to (\>=) 15 at screening and baseline (Day -1).
4. Has stable Screening and baseline (Day-1) PANSS and NSFS total scores (less than \[\<\] 20 percent \[%\] change).
5. Have had a structural brain magnetic resonance imaging (MRI) within the preceding year or during screening indicating no concerning structural brain abnormalities or other abnormalities that would interfere with interpretation of functional brain imaging results.

Exclusion Criteria

1. Has a history of cancer (malignancy).
2. Has a positive alcohol and/ or positive drug screen at Screening or Day -1.
3. Is positive for hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibody, or human immunodeficiency virus (HIV) antibody/antigen (confirmatory testing is allowed; most sensitive test should take precedence).
4. Had major surgery, or donated or lost 1 unit of blood (approximately 500 milliliters \[mL\]) within 4 weeks prior to the pretrial/Screening Visit.
5. Has abnormal Screening or baseline laboratory values (\>upper limit of normal \[ULN\] for the respective serum chemistries) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBILI), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT) confirmed upon repeat testing, 5'-nucleotidase (Screening only), and/or abnormal urine osmolality, confirmed upon repeat testing.
6. Meets DSM-5 criteria for substance use disorder or history of alcohol abuse within 1 month prior to Screening Visit.
7. Has a history of claustrophobia or inability to tolerate mock scanner environment during habituation/screening session.
8. Fulfills any of the MRI contraindications on the site standard radiography screening document.
9. Has a history in the last year from the randomization visit or is currently receiving treatment with clozapine.
10. Has a current diagnosis of a significant psychiatric illness other than schizophrenia, per DSM-5 and is in an acute phase or episode.
11. Has a risk of suicide according to the investigator's clinical judgment (example, per C-SSRS positive answers on questions 4 or 5 or has made a suicide attempt within 6 months prior to screening visit).

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No